Pramlintide (TFA)

• Description :

  Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer[1].

• UNSPSC :

  12352209

• Target :

  Amylin Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/pramlintide-tfa.html

• Solubility :

  H2O

• Smiles :

  O=C([C@@H](N)CCCCN)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)CSSC[C@H](NC1=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC5=CC=C(O)C=C5)=O)[C@@H](C)O)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@@H](C)O)=O)CCC4)=O)CCC3)=O)CC(C)C)=O)[C@H](CC)C)=O)CCC2)=O)=O)CC6=CC=CC=C6)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CO)=O)CC7=CNC=N7)=O)C(C)C)=O)CC(C)C)=O)CC8=CC=CC=C8)=O)CC(N)=O)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)[C@@H](C)O)=O)C)=O.OC(C(F)(F)F)=O.[F,Cl,Br,I]

• Molecular Formula :

  C171H267N51O53S2.xC2HF3O2

• Molecular Weight :

  3949.39 (free base)

• References & Citations :

  [1]Maha S Al-Keilani, et al. Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. Clin Pharmacol. 2018 Mar 5;10:23-29.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  Launched